1、Uplifting Biologics from Billion-Dollar Drugs to Billions of PatientsCPHI Online Trend ReportIn Partnership withCPHI Online Trend Report:Uplifting Biologics from Billion-Dollar Drugs to Billions of Patients 2In Partnership withContents07 Contributors08 ReferencesKey takeawaysBiologics and biomanufac

2、turing:An introductionExplore the current landscape of biologics development and production,and what the future holds for these innovative treatments.Strategic considerations for biomanufacturingThe complexity of biologics and biosimilar manufacturing demand a different,more complex set of considera

3、tions than traditional small-molecule drug production.Smart factories,smarter molecules:AI-driven bioproductionTechnologies like AI,machine learning,and automation are reconfiguring the biologics manufacturing process and offer potential for efficiency and accessibility.A Fourth Revolution of biopro

4、duction:Collaborative innovationBiologics manufacturing is in a Fourth Wave of innovation,focusing on collaboration and partnerships.0102030405On the precipice of innovation for all:Concluding thoughts06Key takeawaysIn Partnership withCPHI Online Trend Report:Uplifting Biologics from Billion-Dollar

5、Drugs to Billions of Patients 4In Partnership with01 Key takeawaysKey takeaways 1/2Scaling biologics technology is in a Fourth Wave of innovationThe fourth revolutionary wave of biologics manufacturing marks a transformative chapter in the industrys development,with companies charging towards ultra-

6、large-scale production that will ultimately benefit patients worldwide through improved access to biological therapies at reduced manufacturing costs.Biosimilars are increasing the demand for innovative and at-scale biologics manufacturing Biosimilars are significantly influencing the biologics manu